[Treatment of cystoid macular edema with bevacizumab in course of Irvine-Gass syndrome].

PURPOSE: To determine clinical effect of intravitreal bevacizumab (Avastin) in patients with cystoid macular edema after cataract surgery.

MATERIAL AND

METHODS

Four eyes of four patients treated with 1 intravitreal injection of 1.25 mg Avastin. In three cases duration of cystoid macular edema was less then 4 months, in one eye cystoid macular edema was chronic (more than 4 months). Visual acuity and clinical effect in spectral optical coherence tomography (central retinal thickness and fovea anatomy) was examined before and after intravitreal injection.

RESULTS

Visual acuity improved in 3 of 4 patients. In acute cystoid macular edema final visual acuity was 0.8-0.9, in chronic cystoid macular edema patient visual acuity improved from 0.05 to 0.2. In 3 of 4 patients central retinal thickness decreased and fovea anatomy was normalized. In patient with no clinical and anatomical improvement spectral optical coherence tomography examination revealed epiretinal membrane.

CONCLUSIONS

Intravitreal Avastin may be successful treatment in most Irvine-Gass syndrome cases. The condition that exclude patients from bevacizumab treatment is horizontal (epiretinal membrane), and vertical traction revealed in spectral optical coherence tomography.